文献速递眼底病与葡萄膜炎

既往接受治疗的慢性新生血管性年龄相关性黄斑变性患者接受玻璃体腔注射法瑞西单抗的真实世界长期结局

REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2025-02-17

该回顾性单中心队列研究纳入263只眼(217例)既往接受过治疗的新生血管性年龄相关性黄斑变性(nAMD)患眼,换用法瑞西单抗(IVF)治疗并随访至少12个月;1年内平均注射6.4±2.3次,注射间隔从5.9±1.8周延长至7.6±2.4周(P<0.01),视力无改善(P>0.15),黄斑中心凹厚度(CST)从313.7±96.0µm降至288.2±80.6µm(P<0.01),视网膜下液显著吸收而视网膜内液(IRF)未见显著吸收,31只眼(11.8%)停药、其中4只眼(1.6%)发生眼内炎症。

要点

  • 换用法瑞西单抗后注射间隔由5.9±1.8周延长至7.6±2.4周(P<0.01)。
  • 视力在换药后各时间点均无改善(P>0.15)。
  • CST由313.7±96.0µm降至288.2±80.6µm(P<0.01),视网膜下液显著吸收而IRF未见显著吸收。

核心结论

  • 长期存在的nAMD患眼换用法瑞西单抗后1年内注射间隔显著延长、视力稳定、CST改善,许多患者OCT上液体吸收。

研究设计与样本

  • 回顾性单中心队列研究,纳入既往接受过治疗的nAMD患者,接受玻璃体腔注射法瑞西单抗且随访至少12个月。
  • 共纳入217例患者的263只眼。

主要发现

  • 1年内平均接受6.4±2.3次玻璃体腔注射法瑞西单抗。
  • 换用法瑞西单抗后注射间隔由5.9±1.8周延长至7.6±2.4周(P<0.01)。
  • 换药后各时间点视力均无改善(P>0.15)。
  • 首次注射法瑞西单抗后平均CST下降并维持1年(313.7±96.0µm vs 288.2±80.6µm)(P<0.01)。
  • 视网膜下液在所有时间点均显著吸收(40.8%-50.4%;P<0.01),而IRF未见显著吸收;首次注射后持续存在的液体至1年时34.4%(n=45)吸收。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the real-world outcomes of intravitreal faricimab (IVF) in long-standing neovascular age-related macular degeneration (nAMD) over a 1-year study period. METHODS: Retrospective single-center cohort study of patients with previously treated nAMD receiving IVF with at least 12 months of follow-up. Main outcome measures include injection intervals, visual acuity (VA), and optical coherence tomography features. RESULTS: A total of 263 eyes from 217 patients received 6.4 ± 2.3 IVF injections over 1 year. Injection interval increased after switching to IVF (5.9 ± 1.8 vs. 7.6 ± 2.4 weeks) ( P < 0.01). There was no improvement in VA after switching to IVF at any time period ( P > 0.15). Average CST decreased after the first IVF injection and was sustained for 1 year (313.7 ± 96.0 vs. 288.2 ± 80.6 µ m) ( P < 0.01). There was a statistically significant resolution of subretinal fluid but not IRF at all time points (40.8%-50.4%; P < 0.01). Persistent fluid after the first IVF injection was resolved in 34.4% (n = 45) by 1 year. IVF was discontinued in 31 eyes (11.8%), four (1.6%) that experienced intraocular inflammation. CONCLUSION: Long-standing nAMD eyes switched to IVF experienced a significant extension in injection interval, stable visual acuity, improvement in CST, and resolution of fluid on OCT in many patients over 1 year.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Ambati NR, Leone A, Brill D, et al. REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2025. PMID: 39531583. doi:10.1097/IAE.0000000000004322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。